» Articles » PMID: 37108561

Prognostic Factors Affecting Death in Patients with Rheumatoid Arthritis Complicated by Pneumonia and One-Year Clinical Course: The ANSWER Cohort Study

Abstract

This multicenter retrospective study aimed to clarify the prognostic factors for mortality and changes in treatment modalities and disease activities after the onset of pneumonia (PCP) in patients with rheumatoid arthritis (RA). Data regarding the clinical background, treatment modalities, and disease activity indicators of RA at the onset of PCP (baseline), and 6 months and 12 months after treatment were extracted. Of the 37 patients with RA-PCP (median age, 69 years; 73% female), chemical prophylaxis was administered to 8.1%. Six patients died during PCP treatment. The serum C-reactive protein (CRP) levels and the prednisolone (PDN) dose at baseline in the PCP death group were significantly higher than those in the survivor group. Multivariate analysis using a Cox regression model showed that PDN dose at baseline was a predictor of death from PCP in patients with RA. During the 12 months from baseline, the RA disease activity significantly decreased. A high dose of corticosteroids for RA may result in a poor prognosis when PCP is complicated. In the future, preventive administration techniques must be established for patients with RA who need PCP prevention.

Citing Articles

Machine Learning Models for Prediction of Severe Pneumonia after Kidney Transplantation: A Single-Center Retrospective Study.

Liu Y, Qiu T, Hu H, Kong C, Zhang Y, Wang T Diagnostics (Basel). 2023; 13(17).

PMID: 37685276 PMC: 10486565. DOI: 10.3390/diagnostics13172735.


Risk Factors for Pneumonia in Non-HIV Patients Hospitalized for COVID-19: A Case-Control Study.

Viceconte G, Buonomo A, DAgostino A, Foggia M, Di Fusco A, Pinchera B J Fungi (Basel). 2023; 9(8).

PMID: 37623609 PMC: 10455879. DOI: 10.3390/jof9080838.

References
1.
Katsuyama T, Saito K, Kubo S, Nawata M, Tanaka Y . Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study. Arthritis Res Ther. 2014; 16(1):R43. PMC: 3978920. DOI: 10.1186/ar4472. View

2.
Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H . Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2007; 67(2):189-94. DOI: 10.1136/ard.2007.072967. View

3.
Rekhtman S, Strunk A, Garg A . Incidence of pneumocystosis among patients exposed to immunosuppression. J Am Acad Dermatol. 2019; 80(6):1602-1607. DOI: 10.1016/j.jaad.2018.12.052. View

4.
Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K . Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009; 61(3):305-12. DOI: 10.1002/art.24283. View

5.
. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet. 2019; 394(10200):757-779. PMC: 6727070. DOI: 10.1016/S0140-6736(19)30721-4. View